Status:
COMPLETED
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Malignant Melanoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen
Detailed Description
vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen. Antigens used are Melan-A, Mage-A1...
Eligibility Criteria
Inclusion
- stage III/IV
- fresh frozen tumor-tissue
- age 18-75
- informed consent given
- Karnofsky \>= 70%
Exclusion
- systemic glucocorticoids
- brain metestasis
- other malignancies
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00204607
Start Date
July 1 2004
End Date
January 1 2007
Last Update
April 19 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, University of Tübingen
Tübingen, Germany, 72076